alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 97-7038
WINSTON LLOYD, Plaintiff - Appellant, versus RICHARD LANHAM, Commissioner of Corrections; MELANIE PEREIRA, Deputy Commissioner of Corrections; EARL BESHEARS, Warden; GLENN T.MARROW, Assistant Attorney General, all defendants sued individually and in their official capacity; DOCTOR SEIFERT, sued individually and in her official capacity, Defendants - Appellees. Appeal from the United States District Court for the District ofMaryland, at Greenbelt. Peter J. Messitte, District Judge. (CA97-127-PJM. CA-97-32-PJM) Submitted: March 26, 1998 Decided: April 7, 1998 Before WIDENER and MOTZ, Circuit Judges, and BUTZNER, Senior Circuit Judge. Affirmed by unpublished per curiam opinion. Winston Lloyd, Appellant Pro Se. John Joseph Curran, Jr., Attorney General, Glenn William Bell, OFFICE OF THE ATTORNEY GENERAL OF MARYLAND, Baltimore, Maryland, for Appellees.2 Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).

PER CURIAM: Appellant appeals from the d istrict court's order denying relief on his consolidated 42 U.S.C. § 1983 (1994) complaints. We have reviewed the record and the district court's opinion and find no reversible error. Accordingly, we affirm on the reasoning of the district court. Lloyd v. Lanham , Nos. CA-97-127-PJM; CA-97-32-PJM (D. Md. June 26, 1997). We dispense with oral argument because thefacts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
EXHIBIT 32


                            CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     In connection  with the Quarterly  Report of Momentum  Biofuels,  Inc. (the
"Company")  on Form 10-Q for the period  ending March 31, 2009 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"). I, Gregory
A. Enders, President of the company,  certify,  pursuant to 18 USC Section 1350,
as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002, that to
the best of my knowledge and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information  contained in the Report fairly presents, in all
                material  respects,  the  financial  condition  and  results  of
                operations of the Company.


                                         /s/ Gregory A. Enders
                                         --------------------------------
                                         Gregory A. Enders, President
Date: May 19, 2009
**Exhibit32.1**

**CERTIFICATIONPURSUANT TO**

**18U.S.C. SECTION 1350,**

**ASADOPTED PURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

Each of the undersignedofficers of Spescom Software Inc. (the “Company”) hereby certifies to hisknowledge that the Company’s quarterly report on Form 10-Q for the period endedJune 30, 2006 (the “Report”), as filed with the Securities and ExchangeCommission on the date hereof, fully complies with the requirements ofSection 13(a) or 15(d), as applicable, of the Securities Exchange Act of1934, as amended, and that the information contained in the Report fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.  This certification is provided solely pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, and shall not be deemed to be a part of the Reportor “filed” for any purpose whatsoever.
| Dated:  August 14, 2006 |
|------------------------------|
|                         |
| /s/ Keith  Stentiford        |   |
|                         |
| Keith Stentiford             |
| Chief Executive  Officer     |

 

 
| Dated:  August 14, 2006 |
|------------------------------|
|                         |
| /s/ John W. Low              |   |
|                         |
| John W. Low                  |
| Chief Financial  Officer     |

A signed original of this written statement requiredby Section 906 has been provided to Spescom Software Inc. and will be retainedby Spescom Software Inc. and furnished to the Securities and ExchangeCommission or its staff upon request.

----
<PAGE>

                                                                  EXHIBIT 10.9.3


                             THIRD AMENDMENT TO THE

                       REVOLVING LINE OF CREDIT AGREEMENT

This THIRD AMENDMENT ("Amendment") is dated as of January 1, 2002, by and
between WFS FINANCIAL INC, a California corporation ("WFS"), and WESTERN
FINANCIAL BANK, a federally-chartered savings bank (the "Bank"), and amends the
REVOLVING LINE OF CREDIT AGREEMENT ("Agreement") entered into by the parties on
June 15, 1999, pursuant to the transfer of certain assets of the Bank to WFS.

                                    RECITALS

A.      The Agreement is being amended to reflect differing interest spreads.

                                    AGREEMENT

        In consideration of the mutual promises set forth herein, and in
reliance upon the recitals set forth above, the parties agree as follows:

    1.    CERTAIN DEFINITIONS

          The definition of "INTEREST SPREAD" is hereby amended as follows:

          "INTEREST SPREAD" shall mean (1) 125 basis points over one-month LIBOR
          for unsecured borrowings and, (2) 90 basis points over one-month LIBOR
          for secured borrowings. In both cases, the LIBOR rate used shall be
          the rate on the last day of the prior month.

    2.    Except as specifically amended herein, all terms of the Agreement as
          previously amended by First and Second amendments to the Agreement
          shall remain in full force and effect.

Wherefore, the undersigned have executed this Amendment on the date set forth
below to be effective as of the date first set forth above.

WFS FINANCIAL INC                             WESTERN FINANCIAL BANK

-------------------------------               ----------------------------------
Thomas A. Wolfe, President and                Lee A. Whatcott,
Chief Operating Officer                       Senior Executive Vice President
                                              and Chief Financial Officer

November, 2001
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE AUDITED
CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 1998 AND THE AUDITED CONSOLIDATED
STATEMENT OF OPERATIONS FOR THE TWELVE MONTHS ENDED DECEMBER 31, 1998 TOGETHER
WITH ALL NOTES THERETO AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<EXCHANGE-RATE>                                      1
<CASH>                                       1,831,139
<SECURITIES>                                         0
<RECEIVABLES>                                6,419,712
<ALLOWANCES>                                         0
<INVENTORY>                                  4,275,490
<CURRENT-ASSETS>                            13,989,004
<PP&E>                                      13,821,161
<DEPRECIATION>                             (2,096,513)
<TOTAL-ASSETS>                              29,771,508
<CURRENT-LIABILITIES>                        8,858,311
<BONDS>                                      3,683,604
<PREFERRED-MANDATORY>                       12,846,586
<PREFERRED>                                     60,000
<COMMON>                                        11,511
<OTHER-SE>                                   4,233,532
<TOTAL-LIABILITY-AND-EQUITY>                29,771,508
<SALES>                                     32,977,537
<TOTAL-REVENUES>                            32,977,537
<CGS>                                       29,481,264
<TOTAL-COSTS>                                7,903,882
<OTHER-EXPENSES>                             3,292,267
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              25,345
<INCOME-PRETAX>                            (7,781,366)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (7,781,366)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (7,781,366)
<EPS-PRIMARY>                                   (0.99)
<EPS-DILUTED>                                   (0.65)
        

</TABLE>
**www.iata.org** International Air Transport Association 1201 F. Street, NW , Suite 650 Wa shington, D.C. 20004 (202) 628 9292 Federal Aviation Administration Airworthiness Directives: The Boeing Company Airplanes Docket No. FAA

- 2014

- 0780 Directorate Identifier 2014

- NM

- 168

-AD To whom it may concern, On behalf of the Secretary of the International Air Transport Association’s (IATA) Unit Load Device Panel (ULDP), I am writing to request a 30 day extension for the above referenced proposed FAA new airworthiness directive (AD)

. The proposed AD, once effective, would not only affect U.S. registered aircraft but also aircraft of the same types worldwide through the Boeing Company’s Aircraft We ight & Balance Manuals. As such, the IATA ULDP has been investigating the technical specifications of the testi ng methods as well as evaluating several potential alternative methods of compliance that could alleviate the significant economic impact without impacting safety. We need more time to complete this evaluation. One challenge we have encountered in this p rocess is that we are not aware of any airline that has received the Boeing test reports, making it more difficult to substantiate other potential methods in reference to the specific testing case used by the AD. Thank you for your consideration and we ap ologize for the late submission of this request. Best regards,

Douglas E. Lavin Vice President, Member and External Relations IATA (202) 628 9292 lavind@iata.org
ANNUAL RECLAIM AUDIT

PAGE 3 - 3 MARCH 2011 

### energy crisis. Even though there was a programmatic r**eduction to Compliance Year 2009 NOx holdings as part of the January 2005 rul**  **e amendments, Compliance Year 2009 NOx emissions still achieved aggrega** **te RECLAIM emission reduction goals and were below the total all** **ocations by 29%. Given the fact that there were programmatic reductions in NOx a**  **llocations starting with Compliance Year 2007 yet the percentage of leftover N**  **Ox RTCs in the program remains at 20% or higher for the last five compliance ye** **ars, including Compliance Year 2009. There may be other forces at pla** **y to cause such results in addition to actual emission reductions implemented** **through the application of air pollution control systems by RECLAIM facilities. Pot** **entially, the effects of the nation’s economic downturn and slow recovery over the last**  **couple of years may also be a contributor to lower aggregate NOx and SOx**  **emissions in the RECLAIM universe. Whether this development has short t** **erm or long lasting impacts is yet to be seen.** 

Table 3-1 Annual NOx Emissions for Compliance Years 1994 thro ugh 2009

Compliance Year Audited

Annual NOx Emissions 1 (tons) Audited

Annual NOx Emissions Change from 1994 (%) Total

NOx RTCs2 (tons) NOx

RTCs Left Over (tons) NOx

RTCs Left Over (%) **1994 25,420**  **0% 40,534**  **15,114 37%**  **1995 26,632**  **4.8% 36,484**  **9,852 27%**  **1996 24,414**  **-4.0% 32,742**  **8,328 25%**  **1997 21,258**  **-16% 28,657**  **7,399 26%**  **1998 21,158**  **-17% 24,651**  **3,493 14%**  **1999 20,889**  **-18% 20,968**  **79 0.38%**  **2000 19,148**  **-25% 17,208**  **-1,940 -11%**  **2001 14,779**  **-42% 15,617**  **838 5.4%**  **2002 11,201**  **-56% 14,111**  **2,910 21%**  **2003 10,342**  **-59% 12,485**  **2,143 17%**  **2004 10,134**  **-60% 12,477**  **2,343 19%**  **2005 9,642**  **-62% 12,484**  **2,842 23%**  **2006 9,152**  **-64% 12,486**  **3,334 27%**  **2007 8,794**  **-65% 11,046**  **2,252 20%**  **2008 8,346**  **-67% 10,705**  **2,359 22%**  **2009 7,317**  **-71% 10,377**  **3,060 29%** 

**1 The RECLAIM universe is divided into two cycles with**  **compliance schedules staggered by six months. Compliance years for Cycle 1 facilities run**  **from January 1 through December 31 and Cycle 2 compliance years are from July 1 through June 3** **0.**

**2 Total RTCs = Allocations + Converted ERCs.**
Editorial Note on Part 314
Editorial Note: Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

§ 314.410 Imports and exports of new drugs. ( a ) *Imports.* ( 1 ) A new drug may be imported into the United States if: ( i ) It is the subject of an approved application under this part; or
( ii ) it complies with the regulations pertaining to investigational new drugs under part 312; and it complies with the general regulations pertaining to imports under subpart E of part 1.
( 2 ) A drug substance intended for use in the manufacture, processing, or repacking of a new drug may be imported into the United States if it complies with the labeling exemption in § 201.122 pertaining to shipments of drug substances in domestic commerce.
( b ) *Exports.* ( 1 ) A new drug may be exported if it is the subject of an approved application under this part or it complies with the regulations pertaining to investigational new drugs under part 312.
( 2 ) A new drug substance that is covered by an application approved under this part for use in the manufacture of an approved drug product may be exported by the applicant or any person listed as a supplier in the approved application, provided the drug substance intended for export meets the specification of, and is shipped with a copy of the labeling required for, the approved drug product.
( 3 ) Insulin or an antibiotic drug may be exported without regard to the requirements in section 802 of the act if the insulin or antibiotic drug meets the requirements of section 801(e)(1) of the act.
[50 FR 7493, Feb. 22, 1985. Redesignated at 57 FR 17983, Apr. 28, 1992, and amended at 64 FR 402, Jan. 5, 1999; 69 FR 18766, Apr. 8, 2004]
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1311 Ferrous lactate. ( a ) Ferrous lactate (iron (II) lactate, C6H10FeO6, CAS Reg. No. 5905-52-2) in the trihydrate form is a greenish-white powder or crystalline mass. It is prepared by reacting calcium lactate or sodium lactate with ferrous sulfate, direct reaction of lactic acid with iron filings, reaction of ferrous chloride with sodium lactate, or reaction of ferrous sulfate with ammonium lactate.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 4th ed. (1996), pp. 154 to 155, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food as a nutrient supplement as defined in § 170.3(o)(20) of this chapter and as a color fixative for ripe olives, with no other limitation other than current good manufacturing practice. The ingredient may also be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 350a(g)) or with regulations promulgated under section 412(a)(2) of the act (21 U.S.C. 350a(a)(2)).
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[53 FR 16866, May 12, 1988, as amended at 61 FR 40319, Aug. 2, 1996; 81 FR 5595, Feb. 3, 2016; 88 FR 17724, Mar. 24, 2023]
Office for Domestic Preparedness 

U.S. Department of Homeland Security 

Washington, DC 20531

ODP Information Bulletin 

No. 157 March 30, 2005 

TO All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

 All Core City/Core County Points of Contact 

 All State Homeland Security Directors 

FROM: Matt Mayer 

 Acting Executive Director 

SUBJECT: Stipends for Volunteer Responders 

This Information Bulletin expands allowable costs previously articulated in Information Bulletin 

#141, which clarified overtime and backfill allowable costs for volunteer responders. Under 

previous guidance, stipends were only permitted for unpaid volunteer firefighters to attend ODP 

training and exercises. 

Based on feedback from states, ODP is broadening allowable stipends to include all volunteer 

responders, such as urban search and rescue teams and emergency medical service volunteers. 

This guidance applies to current and previous fiscal year funding for ODP grant programs. 

Please be aware this does not include volunteers such as American Red Cross or Community 

Emergency Response Team members. In addition, states and territories are reminded to submit 

to their assigned Preparedness Officer a written justification and reimbursement policy detailing: 

1) the difficulty states and locals are facing in scheduling responders to participate as unpaid 

volunteers; and 2) why volunteer responders who are willing to provide time without pay are 

unwilling to participate in related training and exercises, and that paying volunteers is a primary 

factor in enticing them to participate in training and exercises. The justification must explain 

how participation in ODP-approved training and exercises makes participants better at the work 

they perform during their regular volunteer duties. Finally, the state should develop and submit 

to their Preparedness Officer a policy for the standardized stipend amount to be provided for 

participation in training and exercises. 

For further information on this Information Bulletin please contact your Preparedness Officer, or 

the Centralized Scheduling and Information Desk at 800-368-6498.
###### Editorial Note on Part 178

#### Editorial Note:

Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 178.3860 Release agents.

Substances listed in paragraph (b) of this section may be safely used as release agents in petroleum wax complying with § 178.3710 and in polymeric resins that contact food, subject to the provisions of this section.

(a) The quantity used shall not exceed the amount reasonably required to accomplish the intended technical effect or any limitations prescribed in this section.

(b) Release agents:

| List of substances | Limitations |
| --- | --- |
| Erucamide (erucylamide) | |
| Formaldehyde, polymer with 1-naphthalenol (CAS Reg. No. 25359-91-5) | For use only as an antiscaling or release agent, applied on the internal parts of reactors employed in the production of polyvinyl chloride and acrylic copolymers, provided that the residual levels of the additive in the ploymer do not exceed 4 parts per million. |
| *N,N′*-Dioleoylethylenediamine | For use only in polyvinyl chloride films in amounts such that the concentration of the substance in these films in the form in which the films contact food shall not exceed 0.055 milligram of the substance per square inch of film. |
| Oleyl palmitamide | |
| Polybutene, hydrogenated; complying with the identity prescribed under § 178.3740(b) | For use only subject to the limitations prescribed for hydrogenated polybutene under § 178.3740(b). |
| Poly(vinyl acetate/vinyl *N-*octadecylcarbamate) (CAS Reg. No. 70892-21-6) produced by the reaction between stoichiometrically equivalent amounts of octadecyl isocyanate and vinyl alcohol/vinyl acetate copolymer; minimum average molecular weight is 500,000 | For use only in application to the backing of pressuresensitive adhesive tapes at levels not to exceed 0.2 milligram per square centimeter (1.29 milligrams per square inch) of backing. |
| Rice bran wax | For use only in plastics intended for contact with dry foods identified as Type VIII in table 1 of § 176.170(c) of this chapter, at levels not in excess of 1.0 percent by weight of the polymer. |
| Saturated fatty acid amides manufactured from fatty acids derived from animal, marine, or vegetable fats and oils | |
| Stearyl erucamide | |

[42 FR 14609, Mar. 15, 1977, as amended at 44 FR 69649, Dec. 4, 1979; 46 FR 51902, Oct. 23, 1981; 61 FR 25396, May 21, 1996; 61 FR 42381, Aug. 15, 1996]
§ 1312.30 Schedule III, IV, and V non-narcotic controlled substances requiring an import and export permit. The following Schedule III, IV, and V non-narcotic controlled substances have been specifically designated by the Administrator of the Drug Enforcement Administration as requiring import and export permits pursuant to sections 201(d)(1), 1002(b)(2), and 1003(e)(3) of the Act (21 U.S.C. 811(d)(1), 952(b)(2), and 953(e)(3)): ( a ) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product.
( b ) [Reserved]
[52 FR 17291, May 7, 1987, as amended at 64 FR 35930, July 2, 1999; 83 FR 48953, Sept. 28, 2018; 85 FR 51645, Aug. 21, 2020]
EXHIBIT 99.1



                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the CirTran  Corporation  (the "Company")  Quarterly
Report on Form  10-QSB/A for the period  ending March 31, 2002 as filed with the
Securities and Exchange  Commission on the date hereof (the "Report"),  I, Iehab
J. Hawatmeh,  President and Chief  Financial  Officer of the Company,  do hereby
certify,  pursuant to 18 U.S.C.  Section 1350 as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

         1. The Report fully complies with the  requirements of Section 13(a) or
15(d) of the Securities and Exchange Act of 1934, as amended; and

         2. The  information  contained in the Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.


Date:  September 30, 2002                            /s/ IEHAB J. HAWATMEH
                                                         ___________________
                                                         Iehab J. Hawatmeh
                                                         President and
                                                         Chief Financial Officer